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Abstract 
The International Classification of Diseases (ICD) and the Diagnostic and Statistical Manual (DSM) are 
routinely used in diagnosing illicit substance use disorders, but for people taking prescribed opioids 
they remain controversial. In pain medicine the concept of ‘Addiction’ is preferred with reduced 
emphasis on tolerance and withdrawal.  This paper examines the prevalence and characteristics of 
pharmaceutical opioid dependence/disorder according to ICD, DSM and the pain medicine concept 
of ‘Addiction’, among chronic non-cancer pain (CNCP) patients prescribed opioids. In the current 
study we used data from a national sample of 1,134 people prescribed opioids for CNCP. Past 12 
month ‘Addiction’ (based on Pain Medicine definition), DSM and ICD dependence definitions were 
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assessed using the Composite International Diagnostic Interview. 
 
Twenty-four percent of the cohort met criteria for ‘Addiction’, 18% for DSM-5 use disorder and 19% 
for ICD-11 dependence. There was ‘substantial’ concordance between ‘Addiction’ and both DSM-5 
use disorder and ICD-11 dependence, though concordance was much greater with ICD-11 
dependence (kappa’s 0.63, 0.79, respectively). Participants meeting criteria for ‘Addiction’ only were 
older, less likely to engage in non-adherent behaviours, self-reported fewer problems or concerns 
with their medication, and had lower rates of psychological distress than those who also met DSM-5 
and ICD-11 criteria. 
 
The definition of ‘Addiction’ captures a larger group of patients than other classification systems, and 
includes people with fewer ‘risk’ behaviours. Despite removal of tolerance and withdrawal for 
prescribed opioid use for DSM-5, we found that ‘Addiction’ was more closely related to an ICD-11 




There has been increasing concern about risks for problematic use of pharmaceutical opioids in 
people prescribed opioids for chronic non-cancer pain (CNCP) [7]. Understanding the nature and 
extent of this issue has been limited due to inconsistency in how problematic opioid use is defined 
[28; 29; 36]. 
 
The International Classification of Diseases (ICD) and the Diagnostic and Statistical Manual (DSM) are 
commonly used in illicit substance use research and clinical practice (See Appendix A for specific 
operationalisations, available online as Supplemental Digital Content at 
http://links.lww.com/PAIN/A251). In the field of pain medicine, however, they remain controversial 
[3; 29]; tolerance and withdrawal are considered normal physiological consequences of long-term 
opioid use rather than indicators of problems. Other features are emphasised [21]. 
 
‘Addiction’, as defined by the American Academy of Pain Medicine, American Pain Society and 
American Society of Addiction Medicine [28] is behaviour including one or more of the following, 
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impaired control over drug use, compulsive use, continued use despite harm, and cravings. A recent 
consensus statement from the Analgesic, Anaesthetic, and Addiction Clinical Trial Translations, 
Innovations, Opportunities, and Networks (ACTTION) group [29] has supported and recommended 
this definition in patients who have been prescribed medication for pain [25].  
 
DSM-5 similarly specifies tolerance and withdrawal are not features of opioid use disorder in people 
taking opioids “solely under medical supervision” [2].. In an earlier paper examining DSM vs ICD 
definitions, DSM-% did not agree well with DSM-IV, ICD-10 or ICD-11 (preliminary criteria) [11]. ICD-
11 displayed the best model fit [11]. For a comparison of the features across the different 
classification systems see Table 1.  
 
Previous estimates of problematic opioid use in CNCP vary: 8-12% for ‘addiction’ [36], DSM-5 lifetime 
pharmaceutical opioid use disorder ranged from 18.8% [11] to 41.3% [4] and lifetime ICD-11 opioid 
dependence 9.9% [11]. However, assessment methods varied across studies, from examining clinical 
notes to administering a structured, well-validated questionnaire.  
 
There has been no contrast of ICD and DSM definitions and the pain medicine concept of ‘Addiction’ 
in a sample of patients prescribed opioids for CNCP. This paper uses data from a large, national, 
community cohort of people prescribed opioids for CNCP, to examine: 
1. The prevalence of people meeting criteria for the different definitions of opioid dependence 
and use disorder (DSM and ICD), and ‘Addiction’ 
2. The degree of concordance between ‘Addiction’, DSM-IV, ICD-10 and ICD-11 ‘pharmaceutical 
opioid dependence’, and the DSM-5 ‘opioid use disorder’; 
3. The socio-demographic and clinical characteristics of persons meeting the different sets of 
criteria for ‘Addiction’, DSM-5 and ICD-11; and 
4. A comparison between those who meet criteria for ‘Addiction’ and those that do not meet 
criteria for any problematic use (i.e. DSM-IV, ICD-10, ICD-11 dependence and DSM-5 use 
disorder) and those who meet criteria for ‘Addiction’ only with those who meet criteria ICD-





Study design and setting 
The Pain and Opioid IN Treatment (POINT) study was designed to document patterns of 
pharmaceutical opioid use, and risk of adverse events and outcomes, in a prospective cohort of 
patients who were prescribed opioids for chronic non-cancer pain. The methodology of this cohort 
has been described in detail elsewhere [6]. The study was approved by the Human Research Ethics 
Committee of UNSW Australia (HREC reference: # HC12149). The current study is based on data 
collected at the two-year time point. Included in the current paper is a sample of 1,134 participants 




At study enrolment POINT participants were: 18 years or older; taking opioids for CNCP for more 
than 6 weeks; competent in English; mentally and physically able to undertake telephone and self-
completion interviews; without serious cognitive impairments; living with chronic non-cancer pain; 
prescribed an opioid such as morphine, oxycodone or fentanyl (Schedule 8 in the Australian 
classification of ‘drugs of dependence’ and subject to additional regulatory controls regarding 
manufacture, supply, distribution, possession and use [32]. A history of injecting drug use was not an 
exclusion criterion, but those currently prescribed pharmaceutical opioids for opioid substitution 
therapy (OST) for heroin dependence or taking opioids for cancer pain were not eligible. Of the 2,091 
participants assessed for eligibility, 90% (n=1873) were eligible and 1514 completed the baseline 
interview (n=201 refused after being deemed eligible and 100 were unable to be contacted). We had 
a completion rate of 82% (n=1,245) at the two-year time point; 113 participants have withdrawn over 
the two-years, 45 have died and 111 participants had discontinued pharmaceutical opioid use 12 
months or more prior to interview.  
 
Phone interviews were conducted by trained interviewers who had received training in the computer 
assisted personnel interviewing survey schedule. Interviewers had a minimum 3-year health or 
psychology degree, were trained in how to respond to reports of suicidal thoughts or suicidal plans, 
and were provided with glossaries of chronic pain medications and conditions. 
 
The measures, tools, and domains collected were based on recommendations made under the 
auspices of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials 
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(IMMPACT) [13; 33]. The six core domains identified as being important in measuring core outcomes  
included pain, physical functioning, emotional functioning, participant ratings of improvement and 
satisfaction with treatments, symptoms and adverse events and participant disposition. Full details of 
the measures used in the study have been reported elsewhere [6]. 
 
Assessment of DSM and ICD dependence and pharmaceutical opioid use disorders and ‘Addiction’ 
Pharmaceutical opioid use disorders were assessed using the Composite International Diagnostic 
Interview 3.0 (CIDI) [15]. The CIDI has been used widely in epidemiological studies in many countries 
[12; 16; 26], and has been shown to have excellent inter-rater reliability [15], test–retest reliability 
[15], and concordance with clinician diagnoses [14]. ‘Addiction’, and ICD and DSM diagnoses were 
determined from the CIDI responses. ‘Addiction’ and the criteria and the numbers of patients 
included in the various definitions are reported in Table 1 (see Appendix A for operationalisation of 
criteria, available online as Supplemental Digital Content at http://links.lww.com/PAIN/A251). 
 
For participants who used medications as prescribed (n=928), the criteria of tolerance and 
withdrawal were not included for assessing fit with DSM-5 diagnoses. However, in those who 
endorsed at least one aberrant behaviour, as collected in the Opioid Related Behaviours in Treatment 
(ORBIT) scale, tolerance and withdrawal were included in assessing fit with DSM-5 opioid use 
disorder (n=206). Aberrant behaviours included were injection, tampering, doctor shopping, or 
diversion of opioids. 
 
Pain and physical health measures 
Current pain severity and pain interference were measured by the Brief Pain Inventory [8] as a 
continuous score from zero to 10. Using the Pain Self-Efficacy Questionnaire [1], a cut-off of 30 was 
used, as scores <30 have been shown to indicate less sustainable gains, and to predict a lower rate of 
return to work and/or maintenance of treatment gains [9]. Participants were asked for how long they 
had been in pain and from how many prescribers they had received their medication. Health service 
utilisation was defined as ever having surgery for pain, having been in a pain management course, or 
having seen a psychiatrist or psychologist. 
 
The Short Form 12 (SF12) is a measure of general health functioning. It provides a physical and 
mental health component core and there are population norms, with a mean score of 50 and a SD of 
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10. In the current study, we only used the physical dimension. A cut-off of two standard deviations 
below the population mean was used to indicate severity in the current study. 
Medications and problematic opioid use measures 
Daily oral morphine equivalent (OME) doses for the pharmaceutical opioids taken by the cohort were 
estimated following review and synthesis of a range of clinical guidelines [22]. Current average daily 
dose (OME mgs/day) was calculated using opioid consumption from a one-week medication diary 
completed as part of the 2-year interview. OME were calculated for the 1,035 participants that 
reported past week opioid medication consumption.  
 
The Prescribed Opioids Difficulty Scale (PODS) was used to measure participants' current problems 
and concerns about using prescribed opioids [31]. We used a continuous score on both the problems 
and the concerns domain on the PODS. The problems domain includes items such as “caused me to 
have difficulty remembering”, “caused me to lose interest”, and “caused me to feel depressed”. The 
concern domain includes items such as preoccupation with medication, needing a higher dose, 
wanting to cut down, feeling dependent on medication and medication causing problems in work 
and social settings alert [31].  
 
The ORBIT is a 10-item measure of aberrant or non-adherent behaviours such as doctor shopping, 
diversion and other examples of unsanctioned use of medications. Each item is scored between zero 




Mental health and substance use 
Depression and generalized anxiety disorder were measured by the PHQ-9 and GAD-7 modules of the 
Patient Health Questionnaire [17; 18]. Previously validated cut-offs were used as follows: moderate 
to severe depression was defined as a score of ≥ 10 on the PHQ-9 [17] and moderate to severe 
anxiety was defined as a score of ≥ 10  on the GAD-7 [30]. 
A score of ≥ 3 on the Primary Care PTSD screen (PC-PTSD) was used to indicate PTSD [23]. 
Participants were asked about lifetime and past 12 month alcohol and illicit drug use. Lifetime drug 
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and alcohol use disorders (using ICD-10 dependence criteria) were assessed via the alcohol and drug 
use module of the Composite International Diagnostic Interview (CIDI) [37].   
 
The following questions on childhood maltreatment were asked, based on questions by Sansone [24] 
: “Before the age of 16, did you experience sexual abuse, physical abuse, emotional abuse, physical 
neglect, emotional and/or did you witness any violence." . In the current study only data from the 
sexual, physical and emotional abuse questions were used and were combined into one dichotomous 
variable of ‘any childhood abuse’. 
 
Data analysis 
Analyses used STATA, version 12.0 (Stata Corporation, College Station, TX, USA). We reported the 
frequency of participants meeting each criterion for pharmaceutical opioid use disorder and 
dependence according to the five classification systems.  We also examined the concordance 
between numbers of participants meeting criteria for each definition of disorder and concordance 
between each of the ‘Addiction’ criterion and the other diagnostic systems. Kappa, bias adjusted 
kappa (BAK), sensitivity, specificity and positive and negative predictive values are reported [20] to 
determine concordance between the ‘Addiction’ symptoms and the other classification systems. 
Kappa interpretation was based those recommended by Viera and Garrett [35], these were; less than 
0 less than chance agreement, 0.01-0.20 slight agreement, 0.21-0.40 fair agreement, 0.61-0.80 
substantial agreement, 0.81-0.99 almost perfect agreement.  
 
Proportions, means and standard deviations were reported. Where data were non-normally 
distributed we reported median and inter-quartile range (IQR). Binary logistic regressions were used 
to examine characteristics associated with concept of addiction compared to those that did not meet 
criteria for any problematic use, according to traditional systems, and those that met criteria for 
‘Addiction’ only, compared with ICD-11 dependence and DSM-5 use disorder. To understand the 
characteristics of the participants who met criteria for ‘Addiction’ (n=271) we compared them with 
those that did not meet criteria for any of the of the classification systems, including, DSM-IV, ICD-10, 
ICD-11 dependence and DSM-5 used disorder (n=823). To understand characteristics of participants 
captured under the concept of ‘Addiction’, that were not included in the traditional classification 
systems of ICD-11 dependence and DSM-5 use disorder, we compared an ‘Addiction’ only group with 
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all who met criteria for DSM-5 (n=104 vs 202 respectively) and all who met criteria for ICD-11 (n=69 
vs 213 respectively). Odds ratios and 95% Confidence Intervals are reported. 
 
Results 
Of the participants, 57% were female (95% CI 54-60), the median age was 60 (IQR 51-69), 43% were 
unemployed (95%CI 40.0-46.2) and they had been prescribed opioids continuously for a median of 7 
years (IQR 4-13). The most common pain conditions reported in the past 12 months were back and 
neck problems (85%, 95%CI 82.8-87.5), followed by arthritis/rheumatism (76%, 95%CI 69.5-75.4) and 
frequent headaches or migraines (33.1, 95%CI 30.0-36.3). The vast majority (87%, 95%CI 84.8-89.1) 
reported the presence of more than one pain condition in the preceding 12 months. 
 
Twenty-five percent of the sample met criteria for physical dependence (as defined by withdrawal), 
and 13% met criteria for tolerance. Prevalence of problematic use differed depending on the 
classification system used (Table 1). The prevalence of Dependence as defined by DSM-IV or ICD-10 
was similar (8.4%, 95%CI 7.0-10.2 and 9.4%, 95%CI 7.8-11.2, respectively). Nineteen percent met 
ICD-11 criteria for Dependence, 18% met criteria for DSM-5 use disorder, and 24% met criteria for 
‘Addiction’. The relationship between ICD-11 and DSM-5 and ‘Addiction’ are presented in Figure 1. 
 
Table 1 and figure 1 here 
 
Measures of concordance between the diagnostic systems are presented in Table 2. There was 
moderate concordance between ‘Addiction’ and DSM-IV, ICD-10 dependence (kappa 0.46 and 0.48, 
respectively). There was substantial concordance between ‘Addiction’ and DSM-5 use disorder and 
ICD-11 dependence (kappa 0.63 and 0.79, respectively). None of the classification systems was 
shown to have excellent concordance with the definition of ‘Addiction’ 
 
Table 2 here 
 
Measures of concordance between the individual criteria for ’Addiction’ and corresponding criteria 
within each of the classification systems are presented in Table 3. Impaired control was the most 
decisive criterion for ‘Addiction’ (PPV 1.00, NPV 0.95). The remaining three criteria showed lower 
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specificity values and much lower bias-adjusted kappas (see Table 3). Amongst the other 
classification systems, given that each comprise polythetic symptom sets, there was only fair-to-
moderate concordance between ‘Addiction’ criteria and DSM-IV and ICD-10 dependence, and DSM-5 
use disorder. There was substantial concordance with impaired control and ICD-11 dependence 
(kappa 0.72), but only slight-to-fair concordance amongst the remaining three criteria. 
 
Table 3 here 
 
Clinical and socio-demographic characteristics of the cohort who meet criteria for ‘addiction’, DSM-5 
‘use disorder’ and ICD-11 ‘dependence’ are presented in Table 4.  Only data for ‘Addiction’, use 
disorder according to DSM-5 and dependence according to ICD-11 are presented. See Appendix B 
(available online as Supplemental Digital Content at http://links.lww.com/PAIN/A251) for results on 
dependence according to DSM-IV and ICD-10. Participants who met criteria for ‘Addiction’, compared 
with those who met no diagnostic criteria for problematic use (DSM-IV, ICD-10, ICD-11 dependence 
and DSM-5 use disorder), were more likely to be male, younger, less likely to be in a married or 
defacto relationship, more likely to report more mental health problems, substance use histories,,, 
greater patient-centred problems, more aberrant or non-adherent medication behaviours associated 
with their opioid use, and a higher OME (Table 4, column E).  
 
No differences were identified between those who did not meet criteria for any dependence/use 
disorder (n=1043) and those who met criteria for ‘Addiction’ only (i.e. did not meet criteria for any 
other classification of ‘dependence’ or ‘opioid use disorder’ n=51, comparison not shown in Table 4). 
 
Compared with those meeting criteria for DSM-5 ‘opioid use disorder’ (n=202), participants who met 
criteria for ‘addiction’ only (i.e. those who met criteria for ‘Addiction’ and not DSM-5, n=202) (Table 
4, column F), referred to as the ‘Addiction’ only group, were significantly less likely to report having 
engaged in non-adherent or aberrant behaviours in the preceding three months, less likely to report 
problems or concerns with their opioid use, less likely to suffer mental health problems or to have 
seen a mental health professional, or to have ever been in substance use treatment, and reported 
fewer side effects, pain interference, poor pain self-efficacy scores. Further, the ‘Addiction’ only 
group was also older and less likely to be unemployed, when compared with those who met criteria 




Compared with those who met criteria for ICD-11 ‘opioid dependence’ (n=213, Table 4, column G), 
the ‘Addiction’ only group (i.e. those who met criteria for ‘Addiction’ only and not ICD-11 
dependence, n=69) was significantly less likely to report aberrant behaviours, problems and concerns 
with their opioid use, but had more mental health problems and were more likely to have ever seen 
a health professional. They were also more likely to be older, in a married/defacto relationship and 
less likely to be unemployed or have completed year 10 of school education. 
 
Table 4 here 
 
Discussion 
There have been difficulties in determining rates of addiction/dependence in people prescribed 
opioids for pain, arising out of a lack of consistency in terminology and measures used [36]. This is 
the first study comparing pain medicine criteria for ‘Addiction’ with standard diagnostic criteria for 
opioid use disorder in people prescribed opioids for CNCP. In this cohort, over the previous 12 
months, 23.9% met criteria for ‘Addiction’, 18.8% for ICD-11 dependence, 17.8% for DSM-5 
pharmaceutical opioid use disorder, and similar proportions met criteria for DSM-IV and ICD-10 
pharmaceutical opioid dependence (9.4% and 8.4%, respectively). There was moderate concordance 
between classifications for ‘Addiction’ and DSM-IV, ‘Addiction’ and ICD-10 dependence and 
substantial concordance between ‘Addiction’ and DSM-5 use disorder and ‘Addiction’ and ICD-11 
dependence. The current study highlights the importance of empirically testing the competing 
definitions of opioid dependence and addiction.  
 
Those who met ‘Addiction’ criteria were significantly more likely than those who did not meet 
criteria for a disorder in any of the classification systems to have greater pain severity, more 
interference from their pain and to have engaged in non-adherent behaviours. They also reported 
more problems and concerns with their opioid medication use, had more mental health issues and a 
greater substance use history.  
 
At face-value therefore, the pain medicine concept of ‘Addiction’ seems to have high sensitivity in 
identifying people with a range of behaviours or traits often associated with opioid dependence (i.e., 
substance use histories and non-adherent behaviours). However, comparisons of those who met 
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criteria for ‘Addiction’ only with those who met criteria for ICD-11 and DSM-5 showed that the 
‘Addiction only’ group were less likely to engage in aberrant behaviours or to have problems with 
their use and had lower rates of psychological distress, and substance use histories. This suggests 
that the addiction definition is capturing a broader group, including some patients who may be 
showing fewer problem behaviours, than those captured by existing diagnostic criteria (i.e. ICD11, 
DSM-5). Finally, there were no differences between the people who were identified only by the 
‘Addiction’ concept (and not by any of the other classification systems) and people who did not meet 
criteria for any of the classification systems.  
 
There are potential clinical implications of the lower threshold for an ‘Addiction’ diagnosis compared 
with other dependence classification systems. It may be argued that the broader ‘addiction’ 
diagnosis may help target clinical strategies such as closer monitoring, safer prescribing and 
dispensing practices and a greater emphasis upon non-opioid interventions. However, a definition 
that is too broad may mean that some people who are not experiencing (and may never develop) 
problematic opioid use may be stigmatised with a label of ‘Addiction’, and may be subjected to 
unnecessary or even potentially counter-therapeutic interventions and/or changes to their treatment 
plans. It is important in CNCP treatment to balance the need for effective pain relief with strategies 
that aim to reduce problematic opioid use. 
 
Another controversial issue in the use of traditional classification systems in pain medicine is whether 
or not tolerance and withdrawal criteria should be included. In the current sample, 25.6% met 
criteria for physical dependence (i.e. withdrawal), and 14.2% met criteria for tolerance. It has been 
argued that the term dependence, according the ICD and DSM classifications, is confusing because it 
includes both physical and psychological dependence [28]. Current definitions of ‘Addiction’ among 
people prescribed long-term opioids for pain have not been empirically derived, although there has 
been a strong clinical consensus supporting the exclusion of the features of ‘tolerance’ and 
‘withdrawal’ in identifying problematic use. Physical dependence is an expected response to 
prolonged exposure to opioids, and where a patient is prescribed opioids for a period of time, they 
may experience withdrawal symptoms when they cease. Psychological dependence, as used in the 
DSM and ICD [28] encompasses a broader behavioural syndrome, see (Table 1). The DSM-5 ‘opioid 
use disorder’ classification attempted to address this issue by conditionally excluding tolerance and 
physical dependence criteria in patients who used opioid medications ‘solely as prescribed’, and 




The development of the ‘addiction’ classification in pain medicine arose out of a concern that too 
many individuals may be inappropriately diagnosed as ‘dependent’ according to the then DSM-IV or 
ICD-10, given theinclusion of withdrawal and tolerance in those diagnostic systems (Ballantyne et al). 
It is of interest that while our study found ‘substantial’ concordance between ‘Addiction’ and DSM-5 
use disorder and between ‘addiction’ and ICD-11 dependence, concordance was far greater for the 
latter. In a previous paper [11], we found that DSM-5 had low concordance compared with other 
classifications (i.e. ICD-11, ICD-10, and DSM-IV). Criticisms of the DSM-5 suggest that the broader use 
of the term opioid use disorder, which encompasses both dependence and abuse criteria, does not 
equate to ‘dependence’. It is unclear which particular patient group the DSM-5 now describes, but it 
appears to be different from those identified by ICD-10, by ICD-11, by DSM-IV dependence and by 
the pain medicine concept of ‘Addiction’.  
 
Of importance, the ICD and DSM classification systems were not designed specifically to address 
pharmaceutical drug use in patients using medications under medical supervision. The salience of 
concepts such as ‘taking a substance in larger amounts or for longer than you intend to’, ‘wanting to 
cut down’, or ‘persistent use despite harms’ are yet to be well understood from the perspective of 
the pain patient. This is especially challenging where medications have positives as well as negatives 
in the context of medical treatment, meaning motivations to continue or to cease medication may be 
unrelated to the construct of dependence, and is an important area for further work. Many such 
behaviours or cognitions (desire to cut down, prolonged use, use despite harms such as side effects) 
occur in patients taking medications for chronic conditions that are not CNS active, and hence may 
not necessarily signify dependence or addiction. This highlights that the current classification 
systems for dependence have been historically developed for substances such as alcohol and illicit 
drugs. This paper examines the best definitions available, but over time diagnostic criteria may be 
refined to better capture problems with medications used in a prescribed context.  
 
Strengths and limitations- 
This study used a large, national community sample of people prescribed opioids for CNCP to 
compare the performance of different diagnostic criteria. However, there is the potential that we did 
not succeed in recruiting a representative sample of people prescribed opioids for chronic pain. To 
investigate this possibility, additional data were collected from a random sample of pharmacies 
(n=71) on the characteristics of all their opioid customers seen during the six week recruitment 
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window. This revealed reassuring similarities with our sample. Among the total number of customers 
recorded as purchasing opioids in these pharmacies, 52% were female (vs 55% in the POINT cohort); 
and 7% were 18-34 years, 55% 35-64 years and 38% 65+ years (vs. 5%, 62% and 33% respectively, in 
the POINT cohort). Two thirds (63%) were prescribed oxycodone (vs. 62% in the POINT cohort), 
16.5% prescribed morphine (vs. 15% in the POINT cohort), and 24% prescribed buprenorphine 
patches (vs. 21% in the POINT cohort).  
 
A further strength herein was that we measured medication nonadherence, unlike other studies that 
have examined the DSM-5 in people prescribed opioids for CNCP [4].  We were therefore able to 
determine which patients were using ‘solely as prescribed’ and so could apply the conditional 
exclusion of tolerance and withdrawal appropriately. 
 
A limitation is the potential bias by reliance on self-report data. For instance, information on chronic 
medical illnesses and mental health problems were not verified through patient records, but the 
rates of pain conditions and findings were similar to those in previous research [5; 27]. Yet, all 
participants were informed that their responses would be de-identified and confidential, an 
assurance found to enhance the validity of self-reported substance use [10]. It is important to note 
that the current study was cross-sectional and future prospective studies, based on community 
samples, are necessary to determine which definitions of ‘Addiction’/dependence are the most 
useful in identifying patients who encounter problems with their pharmaceutical opioid use. Finally, 
the definitions examined in this paper are based on information collected in an interview, rather than 
a diagnosis by a clinician; however, the CIDI has been found to be a reliable and valid method of 





Although our study provides some empirical support for what has previously been based on clinical 
consensus, the ‘addiction’ concept used in pain medicine is broad and encompasses patients that 
may not be at high-risk of problematic opioid use. Even after applying conditional exclusion of 
tolerance and withdrawal, the DSM-5 pharmaceutical use disorder classification appears to capture a 
different patient group from those of other diagnostic systems. Patients identified by ICD-11 opioid 
dependence criteria were nearly all encompassed within the concept of ‘addiction’. ICD-11 opioid 
dependence criteria seem to be the most promising in identifying those patients with CNCP who are 
experiencing significant problems in use, to inform their ongoing treatment planning. 
 
Acknowledgments  
Thanks to Jessica Belcher, Sarah Freckleton, Anika Martin, Bianca Hoban, Teleri Moore Ranira 
Moodley, Kimberley Smith and Rachel Urquhart-Secord, NDARC, for their contribution to data 
collection. We also thank Cerissa Papanastasiou, Burnet Institute, for her contribution to some of the 
POINT data collection in Melbourne Thanks to the Pharmacy Guild of Australia the NSW Pharmacy 
Guild and Pain Australia for their support of this study and assistance with dissemination. Thanks also 
to the POINT advisory committee for their advice on the design and conduct of the study. 
 
This study received funding from the Australian National Health and Medical Research Council 
(NHMRC, #1022522). LD, BL, SN, WH and RPM are supported by NHMRC research fellowships 
(#1041472, #1073858, #1013803, #569738 and #1045318). The National Drug and Alcohol Research 
Centre at the University of NSW is supported by funding from the Australian Government under the 
Substance Misuse Prevention and Service Improvements Grant Fund.  Cerissa Papanastasiou was 
supported by funding provided by the Victorian Drug Law Enforcement Fund. 
 
Conflict of interest 
SN, NL, RB, GC, BL, LD have all been investigators on untied investigator-driven educational grants 
funded by Reckitt Benckiser for post-marketing surveillance studies of buprenorphine-naloxone 
tablets and film, development of an opioid-related behaviour scale, and/or a study examining the 
uptake of opioid substitution therapy among chronic non-cancer pain patients. NL, RB, BL and LD 
15 
 
have received an untied educational grant from Mundipharma for post-marketing surveillance 
studies of Reformulated OxyContin®. MC has received payments from Mundipharma Pty Limited for 




[1] Anderson KO, Dowds BN, Pelletz RE, Edwards WT, Peeters-Asdourian C. Development and initial 
validation of a scale to measure self-efficacy beliefs in patients with chronic pain. Pain 
1995;63(1):77-83. 
[2] Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®): American 
Psychiatric Pub, 2013. 
[3] Ballantyne JC. Assessing the prevalence of opioid misuse, abuse, and addiction in chronic pain. 
Pain 2015;156(4):567-568. 
[4] Boscarino JA, Hoffman SN, Han JJ. Opioid-use disorder among patients on long-term opioid 
therapy: Impact of final DSM-5 diagnostic criteria on prevalence and correlates. Substance 
abuse and rehabilitation 2015;6:83. 
[5] Braden J, Sullivan M. Suicidal ideation, plans and attempts among individuals with chronic pain 
conditions: Data from the National Co-morbidity Survey Replication. The Journal of Pain 
2008;9(4, Supplement 2):70. 
[6] Campbell G, Mattick R, Bruno R, Larance B, Nielsen S, Cohen M, Lintzeris N, Shand F, Hall WD, 
Hoban B, Kehler C, Farrell M, Degenhardt L. Cohort protocol paper: the Pain and Opioids In 
Treatment (POINT) study. BMC pharmacology & toxicology 2014;15(1):17. 
[7] Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA. 
The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic 
Review for a National Institutes of Health Pathways to Prevention WorkshopEffectiveness 
and Risks of Long-Term Opioid Therapy for Chronic Pain. Annals of Internal Medicine 
2015;162(4):276-286. 
[8] Cleeland C. Assessment of Pain in Cancer: Measurement Issues, in Anonymous. Proceedings of 
the Second International Congress on Cancer Pain 1990:47 - 56. 
[9] Coughlan G, Ridout K, Williams AdC, Richardson P. Attrition from a pain management programme. 
British journal of clinical psychology 1995;34(3):471-479. 
[10] Darke S. Self-report among injecting drug users: a review. . Drug and Alcohol Dependence 
1998;51(3):10. 
[11] Degenhardt L, Bruno R, Lintzeris N, Hall W, Nielsen S, Larance B, Cohen M, Campbell G. 
Agreement between definitions of pharmaceutical opioid use disorders and dependence in 
people taking opioids for non-cancer chronic pain (POINT): a cohort study. Lancet Psychiatry 
2015;(in press). 
[12] Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, Levinson D, de 
Girolamo G, Nakane H, Mneimneh Z. Mental disorders among persons with chronic back or 
neck pain: results from the World Mental Health Surveys. Pain 2007;129(3):332-342. 
[13] Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, 
Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, 
Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, 
Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, 
Tollett J, Wernicke J, Witter J. Core outcome measures for chronic pain clinical trials: 
IMMPACT recommendations. Pain 2005;113(1–2):9-19. 
[14] Haro JM, Arbabzadeh-Bouchez S, Brugha TS, de Girolamo G, Guyer ME, Jin R, Lepine JP, Mazzi F, 
16 
 
Reneses B, Vilagut G, Sampson NA, Kessler RC. Concordance of the Composite International 
Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO 
World Mental Health surveys. Int J Methods Psychiatr Res 2006;15(4):167-180. 
[15] Kessler RC, Üstün TB. The World Mental Health (WMH) Survey Initiative version of the World 
Health Organization (WHO) Composite International Diagnostic Interview (CIDI). 
International Journal of Methods in Psychiatric Research 2004;13(2):93-121. 
[16] Kessler RC, Üstün TB. The WHO World Mental Health Surveys: global perspectives on the 
epidemiology of mental disorders: Cambridge University Press New York, 2008. 
[17] Kroenke K, Spitzer R, Williams JBW. The PHQ-9: Validity of a Brief Depression Severity Measure. 
Journal of General Internal Medicine 2001;16(9):606-613. 
[18] Kroenke K, Spitzer RL, Williams JBW, Lowe B. The Patient Health Questionnaire Somatic, Anxiety, 
and Depressive Symptom Scales: a systematic review. General Hospital Psychiatry 
2010;32(4):345-359. 
[19] Larance B, Bruno R, Lintzeris N, Black E, Degenhardt L, Brown A, Nielsen S, Dunlop A, Holland R, 
Cohen M, Mattick RP. Development of the Opioid Related Behaviours In Treatment (ORBIT) 
scale. Drug and Alcohol Dependence Accepted November, 2015. 
[20] Mackinnon A. A spreadsheet for the calculation of comprehensive statistics for the assessment 
of diagnostic tests and inter-rater agreement. Computers in biology and medicine 
2000;30(3):127-134. 
[21] Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA. Systematic 
review: opioid treatment for chronic back pain: prevalence, efficacy, and association with 
addiction. Annals of Internal Medicine 2007;146(2):116-127. 
[22] Nielsen S, Degenhardt L, Hoban B, Gisev N. Comparing opioids: A guide to estimating oral 
morphine equivalents (OME) in research. NDARC Technical Report No. 329: National Drug 
and Alcohol Research Centre, UNSW Australia, 2014. 
[23] Prins A, Ouimette P, Kimerling R, Camerond RP, Hugelshofer DS, Shaw-Hegwer J, Thrailkill A, 
Gusman FD, Sheikh JI. The primary care PTSD screen (PC-PTSD): development and operating 
characteristics. Primary Care Psychiatry 2004;9(1):9-14. 
[24] Sansone RA, Whitecar P, Wiederman MW. The Prevalence of Childhood Trauma Among Those 
Seeking Buprenorphine Treatment. Journal of Addictive Diseases 2009;28(1):64-67. 
[25] Savage S, Covington E, Heit H, Hunt J, Joranson D, Schnoll S. Definitions related to the use of 
opioids for the treatment of pain: A consensus document from the American Academy of 
Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. 
American Pain Society Advocacy and Policy 2001. 
[26] Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, Demyttenaere K, De 
Girolamo G, Haro JM, Jin R. Cross-national associations between gender and mental 
disorders in the World Health Organization World Mental Health Surveys. Archives of general 
psychiatry 2009;66(7):785-795. 
[27] Smith MT, Edwards RR, Robinson RC, Dworkin RH. Suicidal ideation, plans, and attempts in 
chronic pain patients: factors associated with increased risk. Pain 2004;111(1–2):201-208. 
[28] Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox JD, 
Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O'Brien C, Roland CL, 
Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH. Classification 
and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic 
review and recommendations. Pain 2013;154(11):2287-2296. 
[29] Smith SM, Paillard F, McKeown A, Burke LB, Edwards RR, Katz NP, Papadopoulos EJ, Rappaport 
BA, Slagle A, Strain EC, Wasan AD, Turk DC, Dworkin RH. Instruments to Identify Prescription 
Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTTION Systematic 
Review. The Journal of Pain 2015;16(5):389-411. 
[30] Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety 
disorder: the GAD-7. Archives of Internal Medicine 2006;166(10):1092-1097. 
17 
 
[31] Sullivan M, Von Korff M, Banta-Green C, Merrill J, Saunders K. Problems and concerns of patients 
receiving chronic opioid therapy for chronic non-cancer pain. (19 refs.): University of 
Washington, School of Medicine, Department of Psychiatry & Behavioral Science, Box 
356560, Seattle, WA 98195. [E-mail: sullimar@u.washington.edu], 2010. 
[32] Therapeutic Goods Administration. Standard for the Uniform Scheduling of Medicines and 
Poisons (SUSMP). In: Australian Government Department of Health and Ageing editor. 
http://wwwtgagovau/industry/scheduling-poisons-standardhtm Accessed on 05/09/2013, 
2013. 
[33] Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar 
JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, 
McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, 
Stauffer JW, Stein W, Tollett J, Witter J. Core outcome domains for chronic pain clinical trials: 
IMMPACT recommendations. Pain 2003;106(3):337-345. 
[34] Üstün B, Compton W, Mager D, Babor T, Baiyewu O, Chatterji S, Cottler L, Göğüş A, Mavreas V, 
Peters L, Pull C, Saunders J, Smeets R, Stipec MR, Vrasti R, Hasin D, Room R, Van den Brink W, 
Regier D, Blaine J, Grant BF, Sartorius N. WHO Study on the reliability and validity of the 
alcohol and drug use disorder instruments: overview of methods and results. Drug and 
Alcohol Dependence 1997;47(3):161-169. 
[35] Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 
2005;37(5):360-363. 
[36] Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, 
abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 
2015;156(4):569-576. 
[37] World Health Organization. Composite International Diagnostic Interview, Version 3.0. Geneva: 
World Health Organization, 2001. 
 
 
Fig 1: Past 12 month diagnosis of addiction, ICD-11 and DSM-5 
A total – Addiction (n=271, 23.9% of the total sample) 
B total – DSM-5 use disorder (n=202, 17.8% of the total sample) 
C total – ICD-11 (n=213, 18.8%) 
A only – (n=51) 
B only – (n=29) 
C only – (n=5) 
AB – Addiction/DSM-5 (n=167) 
AC – Addiction/ICD-11 (n=201) 




Table 1: Definitions and their operationalisation and prevalence in the POINT cohort 




It is characterized by behaviours that include one or more of the following: impaired control over drug use, compulsive 
use, continued use despite harm, and craving. 
At least one of the following (from CIDI): 
impaired control over drug use, compulsive use, 




A state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt 
cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist. 
Withdrawal (CIDI) 25.6 (23.1-28.2) 
Tolerance A state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the 
drug's effects over time 
Tolerance (CIDI) 14.2 (12.3-16.4) 
DSM-IV 
dependence 
1. Tolerance, as defined by either of the following: 
(a) need for markedly increased amounts of the drug to achieve intoxication or desired effect. 
(b) markedly diminished effect with continued use of the same amount of the drug. 
2. Withdrawal, as manifested by either of the following: 
(a) the characteristic withdrawal syndrome for the drug 
(b) the same (or a closely related) substance is taken to relieve or avoid withdrawal symptoms. 
3. The drug is often taken in larger amounts or over a longer period than was intended. 
4. There is a persistent desire or unsuccessful efforts to cut down or control drug use 
5. A great deal of time is spent in activities necessary to obtain the drug (e.g., visiting multiple doctors or driving long 
distances), to use the drug, or to recover from its effects 
6 Important social, occupational, or recreational activities are given up or reduced because of drug use. 
7. The drug use is continued despite knowledge of having a persistent or recurrent physical or psychological problem 
At least three in the same 12 month period 8.5 (7.0-10.2) 
DSM-5 use 
disorder 
1. Taking the opioid in larger amounts and for longer than intended 
2. Wanting to cut down or quit but not being able to do it 
3. Spending a lot of time getting, using, or recovering from use of the substance 
4. Cravings and urges to use the substance 
5. Not managing to do what you should at work, home or school, because of substance use 
6. Continuing to use, even when it causes problems in relationships 
7. Giving up important social, occupational or recreational activities because of substance use 
8. Using substances again and again, even when it puts the you in danger 
9. Continuing to use, even when the you know you have a physical or psychological problem that could have been 
caused or made worse by the substance 
10. Needing more of the substance to get the effect you want (tolerance) 
11. Development of withdrawal symptoms, which can be relieved by taking more of the substance. 
At least 2 of the 11 in the same 12 month period, 
applying conditional exclusions to the features of 
tolerance and withdrawal where relevant. 
• For people using medications, as prescribed, 
the tolerance and withdrawal criteria are 
not included. 
• For people in the POINT sample, who 
endorsed non-adherent behaviours such as 
injection, tampering, doctor shopping, or 
diversion of opioids, tolerance and 




1. Strong desire or sense of compulsion to take the drug. 
2. Impaired capacity to control drug-taking behaviour in terms of its onset, termination, or levels of use, as evidenced by; 
the drug being often taken in larger amounts or over a longer period than intended; or by a persistent desire or 
unsuccessful efforts to reduce or control drug use. 
3. A physiological withdrawal state when drug use is reduced or ceased, as evidenced by the characteristic withdrawal 
syndrome for the drug, or by use of the same (or closely related) substance with the intention of relieving or avoiding 
withdrawal symptoms. 
4. Evidence of tolerance to the effects of the drug, such that there is a need for significantly increased amounts of the 
drug to achieve intoxication or the desired effect, or a markedly diminished effect with continued use of the same 
amount of the drug. 
5. Preoccupation with drug use, as manifested by alternative pleasures or interests being given up or reduced because of 
drug use, or a great deal of time being spent in activities necessary to obtain, take, or recover from the effects of the 
drug. 
6. Persistent drug use despite clear evidence of harmful consequences , as evidenced by continued use when the 
individual is actually aware, or may be expected to be aware, of the nature and extent of the harm. 
7. The drug use is continued despite knowledge of having a persistent or recurrent physical or psychological problem 
that is likely to have been caused or exacerbated by the drug 





1. Impaired control over substance use: craving, used in larger amounts, for longer, or attempts to cut down 
2. Substance use is a priority in life: time spent using and recovering, other activities reduced due to use 
3. Physiological features: tolerance, withdrawal or use to avoid withdrawal 
Essential features comprise of two of the three 
criteria 
18.8 (16.6-21.2) 
The DSM-IV criteria for substance abuse and substance dependence have  been combined into a single substance use disorder specific to each substance of  abuse within a new "addictions and related disorders" 
category. Each substance use disorder is divided into mild, moderate, and severe subtypes.  Whereas DSM-IV substance abuse diagnostic criteria required only 1 symptom, a DSM-5 diagnosis even for just mild 
substance use disorder now requires at least 2. 



































‘Addiction’   Kappa 0.46 Kappa 0.63 Kappa 0.48 Kappa 0.79 
No   83.1 0.00 88.8 17.3 83.7 1.9 92.5 5.2 
Yes   16.9 100 11.2 82.7 16.3 98.1 7.5 94.8 
DSM-IV dependence 
Kappa 0.46  Kappa 0.55 Kappa 0.88 Kappa 0.57 
No 100 64.6   99.3 55.9 99.4 15.1 100 54.9 
Yes 0.0 35.4   0.7 44.1 0.6 84.9 0.0 45.1 
DSM-5 use disorder Kappa 0.63 Kappa 0.55  Kappa 0.58 Kappa 0.69 
No 95.9 38.4 89.1 7.3   89.8 8.5 94.9 27.2 
Yes 4.1 61.6 10.9 92.7   10.2 91.5 5.1 72.8 
ICD-10 dependence Kappa 0.48 Kappa 0.88 Kappa 0.58   Kappa 0.62 
No 99.8 61.6 98.5 6.3 99.0 52.0   100 50.2 
Yes 0.2 38.4 1.5 93.8 1.0 48.0   0 49.8 
ICD-11 dependence Kappa 0.79 Kappa 0.57 Kappa 0.69 Kappa 0.62   
No 98.7 25.5 88.7 0.0 93.8 23.3 89.6 0.0   
Yes 1.3 74.5 11.3 100.0 6.2 76.7 10.4 100.0   
 
Table 3: Concordance between each ‘Addiction’ criteria and different measures of problematic use in the POINT cohort 
  Sensitivity 












Impaired control Addiction 81.9 100 1.00 0.95 0.87 
 DSM-IV dependence 84.4 86.4 0.36 0.98 0.43 
 DSM-5 opioid use disorder 67.3 90.8 0.61 0.93 0.56 
 ICD-10 opioid dependence 80.2 86.6 0.38 0.98 0.44 
 ICD-11 78.9 94.1 0.76 0.95 0.72 
Compulsive use Addiction 30.6 100 1.00 0.82 0.37 
 DSM-IV dependence 58.3 97.4 0.67 0.96 0.59 
 DSM-5 opioid use disorder 36.1 98.9 0.88 0.88 0.44 
 ICD-10 opioid dependence 54.7 97.6 0.70 0.95 0.58 
 ICD-11 35.2 99.1 0.90 0.87 0.43 
Continued use despite 
harm 
Addiction 19.9 100 1.00 0.80 0.22 
 DSM-IV dependence 44.8 98.9 0.80 0.95 0.54 
 DSM-5 opioid use disorder 25.2 99.7 0.94 0.86 0.32 
 ICD-10 opioid dependence 40.6 98.9 0.80 0.94 0.50 
 ICD-11 23.5 99.6 0.93 0.85 0.29 
Craving Addiction 17.0 100 1.00 0.79 0.17 
 DSM-IV dependence 24.4 98.7 0.72 0.94 0.43 
 DSM-5 opioid use disorder 20.3 99.5 0.89 0.85 0.25 
 ICD-10 opioid dependence 36.8 99.3 0.85 0.94 0.48 
 ICD-11 19.7 99.6 0.91 0.84 0.24 
 
 
Table 4: Opioid use and health service utilisation of the POINT cohort according to problematic use definitions (n=1134) 
 A. Do not meet 











E. A (ref) vs B 
(271 vs 823) 
OR (95%CI) 
F. Addiction only vs 
DSM-5 (C.) (ref) 
(104 vs 202) 
OR (95%CI) 
G. Addiction only 
VS ICD-11 (D.)(ref) 
(69 vs 213) 
OR (95%CI) 
History of opioid use        
Years of prescribed opioid use (MDN IQR) 7 (4-13) 6 (4-14) 6 (4-12) 6 (4-12) 99.7 (0.98-1.01) 1.03 (1.00-1.06)* 1.02 (0.99-1.05) 
Years since first symptom of problems related to prescribed 
opioids (MDN IQR) 
5 (3-11.5) 4 (3-8) 5 (3-8) 4 (3-7.5) 0.97 (0.94-1.00)* 1.02 (0.97-1.07) 1.03 (0.97-1.09) 
Current OME (MDN, IQR)
#
 65.0 (34.2-150.0) 104.2 (45.0-178.7) 111 (50-180) 111 (47.4-180) 1.00 (1.00-1.00)* 1.00 (1.00-1.00) 1.00 (1.00-1.00) 
Past 3 month non-adherence score (ORBIT) (MDN, IQR) 0 (0-1) 1 (0-2) 1 (0-3) 1 (02) 1.27 (1.18-1.38)*** 0.78 (0.68-0.90)** 0.86 (0.74-1.00)* 
Problems with prescribed opioids (PODS) score (MDN, IQR) 3 (0-8) 9 (2-19) 14 (5-21) 11 (4-21) 1.09 (1.07-1.10)*** 0.91 (0.89-0.94)*** 0.92 (0.90-0.96)*** 
Concerns with prescribed opioids (PODS) score (MDN, IQR) 4 (0-8) 12 (8-16) 12 (8-20) 12 (8-20) 1.19 (1.16-1.22)*** 0.89 (0.85-0.93)*** 0.87 (0.82-0.91)*** 
% opioid side effects (PADT) 75.3 (72.3-78.2) 81.9 (76.8-86.1) 86.6 (81.2-90.7) 83.6 (77.9-88.0) 1.48 (1.05-2.10)* 0.44 (0.24-0.80)** 0.65 (0.33-1.27) 
Service utilisation        
% more than one opioid prescriber+ 14.6 (12.3-17.2) 19.9 (15.6-25.1) 19.3 (14.4-25.4) 20.2 (15.3-26.2) 1.46 (1.02-2.08)* 0.87 (0.47-1.62) 0.78 (0.36-1.55) 
% ever mental health professional+ 41.6 (38.2-44.9) 61.3 (55.3-66.9) 64.9 (58.0-71.2) 64.3 (57.6-70.5) 2.22 (1.68-2.94)*** 0.59 (0.36-0.95)* 0.57 (0.33-0.99)* 
Clinical correlates        
Median pain severity (SD) 5.0 (1.8) 5.3 (1.8) 5.4 (1.8) 5.3 (1.8) 1.11 (1.02-1.19)* 0.90 (0.79-1.03) 1.01 (0.87-1.18) 
Median pain interference (SD) 5.2 (2.3) 6.0 (2.3) 6.4 (2.2) 6.2 (2.3) 1.18 (1.11-1.26)*** 0.80 (0.72-0.89)*** 0.90 (0.80-1.01) 
% low pain self-efficacy (<30 PSEQ) 37.5 (34.2-40.8) 49.8 (43.9-55.8) 57.9 (50.9-64.6) 52.6 (45.8-59.3) 1.66 (1.26-2.18)*** 0.29 (0.18-0.48)*** 0.65 (0.38-1.13) 
% poor physical functioning (<30 SF-12)+ 72.9 (69.5-76.1) 63.7 (57.1-69.8) 64.6 (56.8-71.7) 62.9 (55.4-69.9) 0.65 (0.47-0.90)** 1.00 (0.58-1.70) 1.15 (0.62-2.12) 
% Current generalised anxiety disorder 11.6 (9.6-14.0) 28.0 (23.0-33.7) 38.6 (32.1-45.6) 32.9 (26.8-39.5) 2.97 (2.12-4.18)*** 0.23 (0.12-0.43)*** 0.31 (0.14-0.65)** 
% Current moderate to severe depression 30.6 (27.5-33.8) 56.8 (50.8-62.6) 67.3 (60.5-73.5) 60.6 (53.8-67.0) 2.99 (2.25-3.96)*** 0.28 (0.16-0.46)*** 0.47 (0.27-0.82)** 
% post-traumatic stress disorder+ 11.3 (9.3-13.7) 24.9 (19.2-29.5) 25.7 (20.1-32.3) 26.3 (20.8-32.7) 2.49 (1.75-3.54)*** 0.60 (0.33-1.10) 0.53 (0.26-1.08) 
% lifetime alcohol use disorder+ 28.3 (25.3-31.4) 39.5 (33.8-45.5) 39.1 (32.6-46.0) 41.3 (34.8-48.1) 1.69 (1.27-2.26)*** 0.97 (0.60-1.58) 0.86 (0.49-1.50) 
% lifetime illicit drug use disorder**+ 11.3 (9.3-16.7) 22.1 (17.6-27.5) 26.2 (20.6-32.8) 25.8 (20.3-32.2) 2.23 (1.56-3.20)*** 0.55 (0.30-1.01) 0.49 (0.23-1.02) 
% family history of problematic use+ 3.8 (2.7-5.5) 8.9 (5.6-14.0) 10.8 (6.7-17.0) 9.9 (6.5-14.7) 2.29 (1.32-3.99)** 0.46 (0.15-1.42) 0.27 (0.06-1.20) 
% ever treatment for SUD + 7.8 (6.1-9.8) 19.2 (14.9-24.4) 24.8 (19.2-31.2) 22.1 (17.0-28.2) 2.9 (1.9-4.2)*** 0.29 (0.14-0.61)** 0.46 (0.21-1.04) 
% childhood maltreatment+ 48.6 (45.2-52.0) 61.3 (55.3-66.9) 62.9 (55.9-69.3) 65.7 (59.0-71.8) 1.67 (1.26-2.21)*** 0.81 (0.50-1.30) 0.60 (0.35-1.05) 
Demographic variables        
% male+ 39.2 (36.0-42.6) 52.0 (46.0-58.0) 56.9 (50.0-63.6) 53.1 (46.3-59.7) 0.60 (0.45-0.79)*** 1.54 (0.96-2.48) 1.10 (0.64-1.89) 
Median age (IQR) 62 (54-71) 56 (46-65) 53 (43-60) 54 (45-62) 0.96 (0.95-0.97)*** 1.06 (1.04-1.09)*** 1.04 (1.02-1.07)** 
% completed year 10 + 81.0 (78.1-83.5) 85.2 (80.5-89.0) 88.6 (83.4-92.3) 89.2 (84.2-92.7) 1.36 (0.93-1.98) 0.48 (0.25-0.91)* 0.34 (0.17-0.68)** 
% Income below AUD 400 + 60.0 (56.6-63.3) 54.2 (48.2-60.1) 50.5 (43.6-57.4) 54.5 (47.7-61.1) 0.79 (0.60-1.04) 1.39 (0.86-2.42) 1.03 (0.59-1.77) 
% unemployed/not in labour force 39.5 (36.2-42.9) 49.8 (43.9-55.8) 55.4 (48.5-62.2) 54.0 (47.2-60.6) 1.51 (1.15-2.00)** 0.54 (0.34-0.88)* 0.55 (0.31-0.95)* 
% married/defacto + 55.2 (51.7-58.5) 49.4 (43.5-55.4) 46.0 (39.2-53.0) 46.0 (39.4-52.8) 0.79 (0.60-1.05) 1.42 (0.88-2.29) 1.94 (1.11-3.39)* 
** includes meth/amphetamine, cannabis, cocaine, ecstasy, hallucinogenics, heroin. + from baseline interview + Did not meet criteria for DSM-IV ICD-10, ICD-11 dependence and DSM-5 opioid use disorder, # based on 
sample of 1,035. OME-Oral morphine equivalents, mg/day
  
 
C 
A 
B 
AB 
ABC AC 
